argenx (NASDAQ:ARGX) PT Raised to $542.00 at Wells Fargo & Company

argenx (NASDAQ:ARGX) had its price objective boosted by equities researchers at Wells Fargo & Company from $478.00 to $542.00 in a report issued on Monday, Benzinga reports. The firm presently has an “overweight” rating on the stock. Wells Fargo & Company‘s price target suggests a potential upside of 37.40% from the company’s current price.

ARGX has been the subject of a number of other research reports. Morgan Stanley lowered their price objective on argenx from $515.00 to $510.00 and set an “overweight” rating for the company in a research report on Tuesday, May 28th. JPMorgan Chase & Co. lowered their price objective on argenx from $560.00 to $500.00 and set an “overweight” rating for the company in a research report on Monday, May 13th. Wedbush reissued an “outperform” rating and issued a $521.00 price objective on shares of argenx in a research report on Thursday, April 18th. Piper Sandler reissued an “overweight” rating and issued a $522.00 price objective on shares of argenx in a research report on Monday, June 17th. Finally, Scotiabank raised their price objective on argenx from $402.00 to $408.00 and gave the stock a “sector perform” rating in a research report on Tuesday, March 26th. Five investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $524.05.

argenx Trading Up 1.7 %

Shares of NASDAQ ARGX opened at $394.47 on Monday. The stock has a market capitalization of $23.44 billion, a PE ratio of -69.69 and a beta of 0.65. The stock’s fifty day simple moving average is $375.35 and its two-hundred day simple moving average is $386.61. argenx has a 12-month low of $327.73 and a 12-month high of $550.76.

argenx (NASDAQ:ARGX) last announced its earnings results on Monday, May 13th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.33). The company had revenue of $412.51 million for the quarter, compared to the consensus estimate of $404.03 million. argenx had a negative net margin of 22.58% and a negative return on equity of 14.14%. During the same period last year, the business posted ($0.52) EPS. On average, equities analysts predict that argenx will post -2.75 earnings per share for the current fiscal year.

Hedge Funds Weigh In On argenx

A number of institutional investors have recently modified their holdings of ARGX. Price T Rowe Associates Inc. MD grew its position in shares of argenx by 49.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 5,504,506 shares of the company’s stock valued at $2,167,235,000 after acquiring an additional 1,830,651 shares during the period. Artisan Partners Limited Partnership grew its position in shares of argenx by 12.2% during the 4th quarter. Artisan Partners Limited Partnership now owns 3,174,477 shares of the company’s stock valued at $1,207,666,000 after acquiring an additional 346,178 shares during the period. Janus Henderson Group PLC grew its position in shares of argenx by 24.8% during the 1st quarter. Janus Henderson Group PLC now owns 2,216,648 shares of the company’s stock valued at $872,690,000 after acquiring an additional 439,889 shares during the period. Capital World Investors grew its position in shares of argenx by 37.0% during the 4th quarter. Capital World Investors now owns 1,961,202 shares of the company’s stock valued at $746,099,000 after acquiring an additional 530,181 shares during the period. Finally, Avoro Capital Advisors LLC grew its position in shares of argenx by 0.3% during the 1st quarter. Avoro Capital Advisors LLC now owns 1,238,467 shares of the company’s stock valued at $487,609,000 after acquiring an additional 3,900 shares during the period. Hedge funds and other institutional investors own 60.32% of the company’s stock.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.